Business Description
Transgene SA
NAICS : 541720
ISIN : FR0005175080
Compare
Compare
Traded in other countries / regions
TNG.FranceTGNA.Germany0OCQ.UKTRGNF.USA IPO Date
2016-03-03Description
Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of its operations is located in France.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.46 | |||||
| Equity-to-Asset | 0.35 | |||||
| Debt-to-Equity | 0.08 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -1.83 | |||||
| Beneish M-Score | -1.68 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -30.7 | |||||
| 3-Year EBITDA Growth Rate | -6.9 | |||||
| 3-Year EPS without NRI Growth Rate | -1.6 | |||||
| 3-Year FCF Growth Rate | -1.8 | |||||
| 3-Year Book Growth Rate | -36.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 3.75 | |||||
| 12-1 Month Momentum % | -20.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.79 | |||||
| Quick Ratio | 1.79 | |||||
| Cash Ratio | 1.56 | |||||
| Days Sales Outstanding | 495.4 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.4 | |||||
| Shareholder Yield % | 0.92 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2421.88 | |||||
| Net Margin % | -1885.81 | |||||
| FCF Margin % | -3169.76 | |||||
| ROE % | -88.82 | |||||
| ROA % | -41.55 | |||||
| ROIC % | -95.2 | |||||
| ROC (Joel Greenblatt) % | -153.49 | |||||
| ROCE % | -52.82 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 115.17 | |||||
| PB Ratio | 8.92 | |||||
| Price-to-Tangible-Book | 9 | |||||
| EV-to-EBIT | -5.64 | |||||
| EV-to-EBITDA | -6.07 | |||||
| EV-to-Revenue | 105.55 | |||||
| EV-to-FCF | -3.34 | |||||
| Price-to-Median-PS-Value | 1.65 | |||||
| Earnings Yield (Greenblatt) % | -17.73 | |||||
| FCF Yield % | -26.85 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:TRGNF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Transgene SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.283 | ||
| EPS (TTM) ($) | -0.238 | ||
| Beta | 12.99 | ||
| Volatility % | 20199.02 | ||
| 14-Day RSI | 3.75 | ||
| 14-Day ATR ($) | 0.000007 | ||
| 20-Day SMA ($) | 1.62 | ||
| 12-1 Month Momentum % | -20.98 | ||
| 52-Week Range ($) | 1.62 - 2.1 | ||
| Shares Outstanding (Mil) | 100.85 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Transgene SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Transgene SA Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Transgene SA Frequently Asked Questions
What is Transgene SA(TRGNF)'s stock price today?
The current price of TRGNF is $1.62. The 52 week high of TRGNF is $2.10 and 52 week low is $1.62.
When is next earnings date of Transgene SA(TRGNF)?
The next earnings date of Transgene SA(TRGNF) is .
Does Transgene SA(TRGNF) pay dividends? If so, how much?
Transgene SA(TRGNF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers